Mayoly reveals its new visual identity to reaffirm its values and ambition

Learn more

During their meeting on 6 December 2016, the Leem Board of Directors (Les Entreprises du Médicament) [The pharmaceutical Industry] appointed a new director, Stéphane Thiroloix, General Manager of the Laboratoires Mayoly Spindler, a “Medium-sized French Laboratory”.

Stéphane Thiroloix is a graduate of the HEC (École des Hautes Études Commerciales [Paris Business School]).
He began his career in 1987 at Roussel Uclaf (now Sanofi), where, for eleven years, he held roles in Marketing/Sales and General Management in South Africa, Mexico, Australia and France.

In 1998, he joined SmithKline Beecham (now GlaxoSmithKline), where he was appointed Vice-President and Director of French Operations, and then Vice-President for Europe in Business Development and Marketing Alliances.

From 2002 to 2007, Stéphane Thiroloix was Vice-President of French Operations and then became Vice-President for Europe and General Manager for France at Bristol-Myers Squibb.

In 2007, he joined the Ispen company’s executive committee as Executive Vice-President of Corporate Development and held this position until 2011, the year he became President of Smith & Nephew’s Advanced Surgical Devices (ASD) Division for Europe, Canada, Japan and Australia.

In 2014, Stéphane Thiroloix became General Manager of Laboratoires Mayoly Spindler.

Mayoly Bela officially opened in November 17th 2016.

Belarus is a major market in CIS region where Mayoly Spindler commercializes its products since 15 years.


Business center “Victoria Olimp”
Bulvard Pabediteliy, 103
Office # 1314

November, 2016 - News

News BabySpasmyl®

In September 2016, Mayoly Spindler launched a new gastroenterology medical device BabySpasmyl®, recommended for the treatment of infant colic, aerophagia, bloating and gastrointestinal disorders in adults, children and infants from one month old.

BabySpasmyl® is a simethicone-based medical device (with recognised physical and mechanical actions against wind).


The BabySpasmyl® dosage:

Infants: 20 drops (around 1 ml) 1-2 times a day
Children: (20 drops, 1-3 times a day)
Adultes : 20-40 gouttes 2-4 fois par jour

BabySpasmyl® is a simethicone-based medical device with physical and mechanical actions, which helps in relieving infant colic, aerophagia, bloating and gastrointestinal disorders in adults, children and infants. It is manufactured by NTC. Read the package leaflet carefully before use. In case of doubt, ask your doctor or pharmacist. This medical device is a regulated healthcare device that, in accordance with this regulation, has the (CE 0426) CE marking, issued by ITALCERT. November 2016.

The marketing of Cholurso 500 in Great Britain marks the beginning of the internationalisation of this product, which, until now, had only been sold on the French market.
 Alverine 60 marks another milestone for our MeteoSpasmyl franchise, achieved through the first marketing of Alverine not combined with simeticone.
Still small progress in terms of turnover, but a huge one for Mayoly Spindler in terms of willingness of presence and ambition across the channel to conquer a British market that is very attractive for our products.

The launch of The 15th edition of the AGA ‘à la Française’ (American Gastroenterology Association) took place on 17 June 2016 in Paris.
Over a hundred French gastroenterologists, as well as gastroenterologists from Algeria, Tunisia, Morocco and Lebanon, attended the event.

During this event, videos analysing major AGA communications and interviews with opinion leaders from around the world were broadcast. Discussions on these advances then fed debates.

This year Doctor Hervé HAGEGE once again coordinated and moderated the filming sessions with Professor Benoît COFFIN, Professor Jean-Christophe SAURIN, Doctor Geoffroy VANBIERVLIET and Professor Matthieu ALLEZ.

There was a new record this year for the 15th edition: the videos and interviews were conducted, filmed and edited, and the debates held with our expert gastroenterologist reporters, in just two weeks, providing AGA ‘à la Française’ attendees with a sneak peek at the latest information.

Also new this year, a mobile app was created in order to facilitate discussions among attendees.

Finally, all of the videos and discussions from the AGA ‘à la Française’ will soon be available on a dedicated platform in order to share this consolidation effort with as many people as possible.

The AGA ‘à la Française’ strongly confirmed the role of Laboratoires Mayoly Spindler as a benchmark company in the field of Gastroenterology.

Cosmoprof North America,  the leading B2B beauty and cosmetics trade show, took place, this year, in Las Vegas.

The exhibition welcomed 1,000 exhibitors and attracted around 30,000 visitors from all over the world.

Our laboratory participated as an exhibitor with the aim of developing awareness of our brand, Topicrem, in the Americas, even though our products are preparing to conquer Canada before the end of the year.


Chophyshot®, your solution to take during periods of overeating

Chophyshot® is an artichoke-based dietary supplement with sweeteners to be taken during periods of festive overindulgence.
Thanks to its compact size containing a single daily dose, you can easily take this 10-ml bottle with you wherever you go.

Chophyshot® has been developed by our Research and Development teams in Chatou. Made from artichoke (11%), it is sugar-free and has an orange and grapefruit flavour.

Chophyshot®  should be taken once a day during periods of overeating.

Chophyshot® will be available in pharmacies from October 2016.
Recommended Retail Price: €1.50

Alcohol 2.6% vol.
Chophyshot® is a dietary supplement to be taken during periods of overeating. This product should not be used as a substitute for a varied diet.
Eat at least five portions of fruit and vegetables a day to stay healthy.
Chophyshot® must not be used by pregnant or breastfeeding women.
It is not advisable to exceed the recommended daily dose (a single daily dose).

Discover it

August, 2016 - News


Please be informed that Mayoly Spindler has no office in Australia.
If you have been contacted or have been proposed a job by a person who identified him/herself as an employee of Mayoly Australia, using an email address with, you are victim of a fraud.

Mayoly Spindler will not accept any liability in the case you would accept or have accepted the job offered in the context of this fraud.

June, 2016 - News


Mayoly Spindler is involved in research on Irritable Bowel Syndrome as a partner of the French Neuro-Gastroenterology Group (GFNG). Like every year, we are participating in the GFNG Annual Meeting at the Embarcadère in Lyon on 25 and 26 June. Please come visit us at our booth where we will be happy to welcome you.
For more information: gfng-2015-lyon